Ranjit Banwait

447 total citations
25 papers, 248 citations indexed

About

Ranjit Banwait is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Ranjit Banwait has authored 25 papers receiving a total of 248 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Genetics, 12 papers in Pathology and Forensic Medicine and 9 papers in Hematology. Recurrent topics in Ranjit Banwait's work include Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Multiple Myeloma Research and Treatments (5 papers). Ranjit Banwait is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), Lymphoma Diagnosis and Treatment (11 papers) and Multiple Myeloma Research and Treatments (5 papers). Ranjit Banwait collaborates with scholars based in United States and France. Ranjit Banwait's co-authors include Irene M. Ghobrial, Edie Weller, Xavier Leleu, Renee Leduc, Steven P. Treon, Stacey Chuma, Aldo M. Roccaro, Paul G. Richardson, Federico Campigotto and Nitin Roper and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

In The Last Decade

Ranjit Banwait

25 papers receiving 243 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ranjit Banwait United States 8 176 149 73 68 67 25 248
A. Hellmann Poland 8 180 1.0× 131 0.9× 60 0.8× 24 0.4× 74 1.1× 28 257
Silvia Imbergamo Italy 10 119 0.7× 62 0.4× 83 1.1× 54 0.8× 60 0.9× 20 224
Helen Marr United Kingdom 10 64 0.4× 31 0.2× 32 0.4× 64 0.9× 43 0.6× 18 188
Sadia Falcioni Italy 9 52 0.3× 75 0.5× 138 1.9× 62 0.9× 101 1.5× 13 260
Vishala T. Neppalli United States 8 36 0.2× 85 0.6× 49 0.7× 62 0.9× 45 0.7× 22 221
Esperanza Lavilla Spain 8 36 0.2× 49 0.3× 82 1.1× 65 1.0× 23 0.3× 12 200
Tuğrul Elverdi Türkiye 7 63 0.4× 37 0.2× 71 1.0× 13 0.2× 34 0.5× 44 164
A.-L. Taksin France 6 106 0.6× 71 0.5× 219 3.0× 103 1.5× 33 0.5× 6 360
Fernando Roncolato Australia 8 48 0.3× 66 0.4× 109 1.5× 57 0.8× 14 0.2× 17 183
Joi Ninomoto United States 11 376 2.1× 300 2.0× 148 2.0× 30 0.4× 118 1.8× 19 407

Countries citing papers authored by Ranjit Banwait

Since Specialization
Citations

This map shows the geographic impact of Ranjit Banwait's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ranjit Banwait with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ranjit Banwait more than expected).

Fields of papers citing papers by Ranjit Banwait

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ranjit Banwait. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ranjit Banwait. The network helps show where Ranjit Banwait may publish in the future.

Co-authorship network of co-authors of Ranjit Banwait

This figure shows the co-authorship network connecting the top 25 collaborators of Ranjit Banwait. A scholar is included among the top collaborators of Ranjit Banwait based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ranjit Banwait. Ranjit Banwait is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rastogi, Vaibhav, et al.. (2021). Prevalence of hepatopancreatic injury and clinical outcomes in patients with COVID-19 in USA. International Journal of Emergency Medicine. 14(1). 68–68. 2 indexed citations
2.
3.
Banwait, Ranjit, et al.. (2020). Convalescent Plasma in COVID-19. HCA Healthcare Journal of Medicine. 1(3). 139–146. 4 indexed citations
4.
Banwait, Ranjit, et al.. (2020). Thrombocytopenia Associated with Increase in Disease Severity and Mortality in COVID-19 Patients. Blood. 136(Supplement 1). 1–1. 2 indexed citations
5.
Ghobrial, Irene M., Robert Redd, Philippe Armand, et al.. (2015). Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenstrom macroglobulinemia. Leukemia. 29(12). 2338–2346. 26 indexed citations
6.
Banwait, Ranjit, Yosra Aljawai, Elizabeth A. Morgan, et al.. (2014). Extramedullary Waldenström macroglobulinemia. American Journal of Hematology. 90(2). 100–104. 43 indexed citations
7.
Manier, Salomon, Siobhan Glavey, Antonio Sacco, et al.. (2013). Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. Blood. 122(21). 3086–3086. 1 indexed citations
8.
Ghobrial, Irene M., Kenneth H. Shain, Ranjit Banwait, et al.. (2013). Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. Blood. 122(21). 1947–1947. 3 indexed citations
9.
Ghobrial, Irene M., Federico Campigotto, Timothy J. Murphy, et al.. (2013). Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 121(8). 1296–1303. 37 indexed citations
10.
Ghobrial, Irene M., Stacey Chuma, Ranjit Banwait, et al.. (2013). Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood. 122(21). 4402–4402. 3 indexed citations
11.
Roccaro, Aldo M., Antonio Sacco, Xiaojing Jia, et al.. (2012). Mechanisms of Activity of the TORC1 Inhibitor Everolimus in Waldenstrom Macroglobulinemia. Clinical Cancer Research. 18(24). 6609–6622. 11 indexed citations
12.
Manier, Salomon, Antonio Sacco, Patricia Maiso, et al.. (2012). Comparative miRNA Expression Profiling of Circulating Exosomes From MGUS and Smoldering Multiple Myeloma Patients. Blood. 120(21). 3975–3975. 2 indexed citations
13.
Ghobrial, Irene M., Morie A. Gertz, Betsy LaPlant, et al.. (2012). Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia.. Journal of Clinical Oncology. 30(15_suppl). 8043–8043. 1 indexed citations
14.
Leleu, Xavier, Wanling Xie, Ranjit Banwait, et al.. (2011). The Role of Serum Immunoglobulin Free Light Chain in Response and Progression in Waldenstrom Macroglobulinemia. Clinical Cancer Research. 17(9). 3013–3018. 36 indexed citations
15.
Banwait, Ranjit, Kevin O′Regan, Federico Campigotto, et al.. (2011). The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemia. American Journal of Hematology. 86(7). 567–572. 36 indexed citations
16.
Paba‐Prada, Claudia E., Ranjit Banwait, Steven P. Treon, & Irene M. Ghobrial. (2011). Incidence of Peripheral Neuropathy in Waldenstrom Macroglobulinemia Patients At Diagnosis,. Blood. 118(21). 3692–3692. 6 indexed citations
17.
Ghobrial, Irene M., Ranjit Banwait, Abdel Kareem Azab, et al.. (2011). Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood. 118(21). 1874–1874. 7 indexed citations
18.
Ghobrial, Irene M., Ranjit Banwait, Tiffany Poon, et al.. (2011). Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood. 118(21). 2705–2705. 2 indexed citations
19.
20.
Leleu, Xavier, Wanling Xie, Meghan Rourke, et al.. (2010). The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia. Blood. 116(21). 3095–3095. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Hellmann Breakdown of academic impact, for papers by Silvia Imbergamo Breakdown of academic impact, for papers by Helen Marr Breakdown of academic impact, for papers by Sadia Falcioni Breakdown of academic impact, for papers by Vishala T. Neppalli Breakdown of academic impact, for papers by Esperanza Lavilla Breakdown of academic impact, for papers by Tuğrul Elverdi Breakdown of academic impact, for papers by A.-L. Taksin Breakdown of academic impact, for papers by Fernando Roncolato Breakdown of academic impact, for papers by Joi Ninomoto
Rankless by CCL
2026